Nutracryst Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 22-12-2024
- Paid Up Capital ₹ 0.10 M
as on 22-12-2024
- Company Age 20 Year, 4 Months
- Last Filing with ROC 31 Mar 2017
- Open Charges ₹ 1.99 Cr
as on 22-12-2024
- Revenue %
(FY 2017)
- Profit 3.44%
(FY 2017)
- Ebitda -89.57%
(FY 2017)
- Net Worth -49.87%
(FY 2017)
- Total Assets -2.24%
(FY 2017)
About Nutracryst Therapeutics
The Corporate was formerly known as M J J Exim Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2017. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.99 Cr.
Rajnish Garg and Anil Sapra serve as directors at the Company.
- CIN/LLPIN
U24233DL2004PTC129013
- Company No.
129013
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Sep 2004
- Date of AGM
30 Sep 2017
- Date of Balance Sheet
31 Mar 2017
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Nutracryst Therapeutics?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Sapra  | Director | 15-Jun-2005 | Current |
| Rajnish Garg | Director | 15-Jun-2005 | Current |
Financial Performance of Nutracryst Therapeutics.
Nutracryst Therapeutics Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 3.44% increase in profit. The company's net worth observed a substantial decline by a decrease of 49.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nutracryst Therapeutics?
In 2017, Nutracryst Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Controlled Atmosphere Projects Private LimitedActive 38 years 1 monthRajnish Garg and Anil Sapra are mutual person
Charges (Loans)
₹19.86 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 1.99 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Aug 2005 | Canara Bank | ₹1.99 Cr | Open |
How Many Employees Work at Nutracryst Therapeutics?
Unlock and access historical data on people associated with Nutracryst Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nutracryst Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nutracryst Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.